Skip to main content
PMC home page
Heart logoLink to Heart
. 1996 Nov;76(5):418–421. doi: 10.1136/hrt.76.5.418

Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections.

A I Günal 1, A Işik 1, H Celiker 1, O Eren 1, H Celebi 1, S Y Günal 1, C Lüleci 1
PMCID: PMC484573  PMID: 8944587

Abstract

Growth factors have been shown to be associated with primary hypertrophic cardiomyopathy. Octreotide, a long acting somatostatin analogue, can prevent the stimulating effect of growth factors and decrease the left ventricular mass in patients with acromegaly. In the light of these results, three patients with primary hypertrophic cardiomyopathy were treated with subcutaneous octreotide (50 micrograms three times a day during the first week and 100 micrograms twice a day for the following three weeks). Initially, two patients were in New York Heart Association class II in and one was in class III. At the end of a four week treatment session all were in class I. There were significant decreases in left ventricular posterior wall thickness, interventricular septum thickness, and left ventricular mass in all three patients. Both left ventricular end diastolic and end systolic diameters had increased in all of the patients at the end of the fourth week. Two of three patients showed improved diastolic filling: their hyperdynamic systolic performance returned to normal. No side effects were observed during octreotide treatment. The considerable improvement obtained with the short term octreotide treatment in patients with primary hypertrophic cardiomyopathy seems promising.

Full text

PDF
418

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brush J. E., Jr, Eisenhofer G., Garty M., Stull R., Maron B. J., Cannon R. O., 3rd, Panza J. A., Epstein S. E., Goldstein D. S. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation. 1989 Apr;79(4):836–844. doi: 10.1161/01.cir.79.4.836. [DOI] [PubMed] [Google Scholar]
  2. Cannon R. O., 3rd, Rosing D. R., Maron B. J., Leon M. B., Bonow R. O., Watson R. M., Epstein S. E. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation. 1985 Feb;71(2):234–243. doi: 10.1161/01.cir.71.2.234. [DOI] [PubMed] [Google Scholar]
  3. Cool D. E., Andreassen P. R., Tonks N. K., Krebs E. G., Fischer E. H., Margolis R. L. Cytokinetic failure and asynchronous nuclear division in BHK cells overexpressing a truncated protein-tyrosine-phosphatase. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5422–5426. doi: 10.1073/pnas.89.12.5422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Devereux R. B., Alonso D. R., Lutas E. M., Gottlieb G. J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986 Feb 15;57(6):450–458. doi: 10.1016/0002-9149(86)90771-x. [DOI] [PubMed] [Google Scholar]
  5. Ezzat S., Ren S. G., Braunstein G. D., Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab. 1992 Dec;75(6):1459–1463. doi: 10.1210/jcem.75.6.1281485. [DOI] [PubMed] [Google Scholar]
  6. Grant M. B., Wargovich T. J., Ellis E. A., Caballero S., Mansour M., Pepine C. J. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation. 1994 Apr;89(4):1511–1517. doi: 10.1161/01.cir.89.4.1511. [DOI] [PubMed] [Google Scholar]
  7. Koga Y., Itaya M., Toshima H. Increased cardiovascular response to epinephrine in hypertrophic cardiomyopathy. Jpn Heart J. 1985 Sep;26(5):727–740. doi: 10.1536/ihj.26.727. [DOI] [PubMed] [Google Scholar]
  8. Lamberts S. W. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 1988 Nov;9(4):417–436. doi: 10.1210/edrv-9-4-417. [DOI] [PubMed] [Google Scholar]
  9. Lim M. J., Barkan A. L., Buda A. J. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med. 1992 Nov 1;117(9):719–726. doi: 10.7326/0003-4819-117-9-719. [DOI] [PubMed] [Google Scholar]
  10. Maron B. J., Bonow R. O., Cannon R. O., 3rd, Leon M. B., Epstein S. E. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med. 1987 Mar 26;316(13):780–789. doi: 10.1056/NEJM198703263161305. [DOI] [PubMed] [Google Scholar]
  11. Maron B. J., Bonow R. O., Cannon R. O., 3rd, Leon M. B., Epstein S. E. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med. 1987 Apr 2;316(14):844–852. doi: 10.1056/NEJM198704023161405. [DOI] [PubMed] [Google Scholar]
  12. Maron B. J., Epstein S. E. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol. 1979 Jun;43(6):1242–1244. doi: 10.1016/0002-9149(79)90160-7. [DOI] [PubMed] [Google Scholar]
  13. Maron B. J., Wolfson J. K., Epstein S. E., Roberts W. C. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986 Sep;8(3):545–557. doi: 10.1016/s0735-1097(86)80181-4. [DOI] [PubMed] [Google Scholar]
  14. McAreavey D., Robertson J. I. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs. 1990 Sep;40(3):326–345. doi: 10.2165/00003495-199040030-00002. [DOI] [PubMed] [Google Scholar]
  15. McIntosh C. L., Maron B. J. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation. 1988 Sep;78(3):487–495. doi: 10.1161/01.cir.78.3.487. [DOI] [PubMed] [Google Scholar]
  16. Merola B., Cittadini A., Colao A., Ferone D., Fazio S., Sabatini D., Biondi B., Saccá L., Lombardi G. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab. 1993 Sep;77(3):790–793. doi: 10.1210/jcem.77.3.8370700. [DOI] [PubMed] [Google Scholar]
  17. Parmar H., Bogden A., Mollard M., de Rougé B., Phillips R. H., Lightman S. L. Somatostatin and somatostatin analogues in oncology. Cancer Treat Rev. 1989 Jun;16(2):95–115. doi: 10.1016/0305-7372(89)90013-3. [DOI] [PubMed] [Google Scholar]
  18. Pearcé P. C., Hawkey C., Symons C., Olsen E. G. Role of calcium in the induction of cardiac hypertrophy and myofibrillar disarray. Experimental studies of a possible cause of hypertrophic cardiomyopathy. Br Heart J. 1985 Oct;54(4):420–427. doi: 10.1136/hrt.54.4.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sahn D. J., DeMaria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978 Dec;58(6):1072–1083. doi: 10.1161/01.cir.58.6.1072. [DOI] [PubMed] [Google Scholar]
  20. Sakata Y. [Tissue factors contributing to cardiac hypertrophy in cardiomyopathic hamsters (BIO14.6): involvement of transforming growth factor-beta 1 and tissue renin-angiotensin system in the progression of cardiac hypertrophy]. Hokkaido Igaku Zasshi. 1993 Jan;68(1):18–28. [PubMed] [Google Scholar]
  21. Tokgözoğlu S. L., Erbaş T., Aytemir K., Akalin S., Kes S., Oram E. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol. 1994 Nov 15;74(10):1072–1074. doi: 10.1016/0002-9149(94)90865-6. [DOI] [PubMed] [Google Scholar]
  22. Toyozaki T., Hiroe M., Hasumi M., Horie T., Hosoda S., Tsushima T., Sekiguchi M. Insulin-like growth factor I receptors in human cardiac myocytes and their relation to myocardial hypertrophy. Jpn Circ J. 1993 Dec;57(12):1120–1127. doi: 10.1253/jcj.57.1120. [DOI] [PubMed] [Google Scholar]
  23. Witzke D. J., Kaye M. P. Myocardial ultrastructural changes induced by administration of nerve growth factor. Surg Forum. 1976;27(62):295–297. [PubMed] [Google Scholar]
  24. Yarden Y., Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem. 1988;57:443–478. doi: 10.1146/annurev.bi.57.070188.002303. [DOI] [PubMed] [Google Scholar]
  25. York E. L., Sproule B. J. Cerebral blood-flow and polycythaemia. Lancet. 1978 Jan 21;1(8056):152–153. doi: 10.1016/s0140-6736(78)90449-x. [DOI] [PubMed] [Google Scholar]
  26. Zink A., Raue F. Somatostatin inhibits the norepinephrine-activated calcium channels in rMTC 6-23 cells: possible involvement of a pertussis toxin-sensitive G-protein. Acta Endocrinol (Copenh) 1992 Oct;127(4):378–384. doi: 10.1530/acta.0.1270378. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES